KHK7791 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Apr 15, 2019 → Dec 31, 2019
NCT ID
NCT03864458About KHK7791 + Placebo
KHK7791 + Placebo is a phase 2 stage product being developed by Kyowa Kirin for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03864458. Target conditions include Hyperphosphatemia.
What happened to similar drugs?
2 of 15 similar drugs in Hyperphosphatemia were approved
Approved (2) Terminated (0) Active (13)
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04766398 | Phase 3 | Completed |
| NCT04767581 | Phase 3 | Completed |
| NCT03864458 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia